您当前所在的位置:首页 > 产品中心 > 产品信息
Ketoprofen_分子结构_CAS_22071-15-4)
点击图片或这里关闭

Ketoprofen

产品号 DB01009 公司名称 DrugBank
CAS号 22071-15-4 公司网站 http://www.ualberta.ca/
分子式 C16H14O3 电 话 (780) 492-3111
分子量 254.28056 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 882

产品价格信息

请登录

产品别名

标题
Ketoprofen
IUPAC标准名
2-(3-benzoylphenyl)propanoic acid
IUPAC传统名
ketoprofen
商标名
Toprec
Orugesic
Kefenid
Oscorel
Alrheumun
Capisten
Dexal
Fastum
Iso-K
Ketopron
Lertus
Menamin
Meprofen
Orudis
Oruvail
Actron
Alrheumat
Epatec
Orudis KT
Profenid
Toprek
别名
m-Benzoylhydratropic acid

产品登记号

PubChem CID 3825
CAS号 22071-15-4
PubChem SID 46505715

产品性质

疏水性(logP) 3.2
溶解度 51 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indication For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Pharmacology Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
Toxicity LD50=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.


Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

Affected Organisms
Humans and other mammals
Biotransformation Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.
Absorption Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Half Life Conventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

Protein Binding 99% bound, primarily to albumin
Elimination In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
Clearance * Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
* Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
* 0.08 L/kg/h
* 0.7 L/kg/h [alcoholic cirrhosis patients]
References
Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [Pubmed]
Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. Pubmed
  • Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. Pubmed